Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder

@article{Abdelrahman2018CommentaryOA,
  title={Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder},
  author={Abdelmageed Abdelrahman},
  journal={International Urogynecology Journal},
  year={2018},
  volume={29},
  pages={1221}
}
  • A. Abdelrahman
  • Published 29 April 2018
  • Medicine
  • International Urogynecology Journal
This was a cost-effectiveness analysis to determine if onabotulinumtoxin A (Botox®) should be offered as a firstline therapy for the treatment of overactive bladder (OAB), before prescribing anticholinergics [1]. The following treatment options were considered: no treatment, nonselective anticholinergics (nACH), selective anticholinergics (aACH) and Botox®. In the no treatment option, patients received no therapy or intervention for OAB. Tolterodine, a nACH, and solifenacin, a sACH, were… Expand

References

SHOWING 1-2 OF 2 REFERENCES
A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder
TLDR
Botox® is a cost-effective therapy for overactive bladder and should be further explored as a first-line option in the treatment paradigm. Expand
A Cost-Effectiveness Analysis of Onabotulinumtoxin A as First-Line Treatment for Overactive Bladder
TLDR
It is demonstrated that it would be cost-effective to offer Botox as a first-time treatment for overactive bladder instead of offering it after anticholinergic failure, and suggested the current treatment paradigm should be reevaluated. Expand